News

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.
Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...
In a recent interview, FDA Commissioner Marty Makary said there “should be nothing political about the FDA.” Recent actions ...
Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...